Daewoong Pharmaceutical Co., Ltd. established I.N. Therapeutics, a company specializing in new drug development.
Daewoong Pharmaceutical Co., Ltd. established I.N. Therapeutics, a company specializing in new drug development.
  • 박정도
  • 승인 2020.09.15 13:51
  • 최종수정 2020.09.15 12:57
  • 댓글 0
이 기사를 공유합니다

 

[Infostock Daily=Reporter Park Jeong-Do] Daewoong Pharmaceutical has established I.N. Terrapeutics, a new drug development company, to improve the flexibility and acceleration of new drug R & D.

I.N. Traputics is a biotech that injects Daewoong Pharmaceutical's ion channel new drug development platform and Nav1.7 non-drug analgesics, hearing loss treatment, and brain disease treatment. I.N. Traputics has the world's best ion channel evaluation platform and development know-how through the development of ion channel new drugs, which are promising targets of various CNS (central nervous system) diseases for more than 10 years.

Ion channel platform technology has been uniquely competitive with technology that overcomes high-level evaluation method known as limit in ion channel development. Lead pipeline Nav1.7 non-drug analgesics (DWP17061), developed based on platforms, is a candidate for developing First-in-Class medicines. Global pharmaceutical companies are also expected to be developed as a global innovative drug as a target-verified substance that is being developed as a target.

Nav1.7 Non-drug Analgesics (DWP17061) has submitted the Phase I clinical trial plan (IND) in Australia and plans to conduct the first dose of it to health workers by the first half of next year to conduct safety and drug dynamics tests. In preclinical treatment, the drug showed superior body dynamics compared to competitors in the body after medication, and it was confirmed that it has excellent efficacy compared to nonsteroidal anti-inflammatory drugs (NSAIDs), which are typical analgesics for osteoarthritis.

With the establishment of Biotech, Park Jong-deok, CEO of Kolon Pharmaceutical Development Division, who has a wide history of new drug development and new business development for 25 years in the pharmaceutical industry, was newly appointed. Park Jong-duk has gained experience in clinical development, product development and marketing in the field of hematologic cancer and hepatopathology treatment at Bayer Schering and Novartis, global pharmaceutical companies.

Reporter Park Jeong-Do newface0301@naver.com

 


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.